subject area of
- 2022 Canadian Cardiovascular Society Guideline for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Adults Journal Articles
-
S odium‐glucose co‐transporter‐2 inhibitors are associated with kidney benefits at all degrees of albuminuria: A retrospective cohort study of adults with diabetes Journal Articles - Addendum to Policies, Guidelines and Consensus Statements: Pharmacologic Management of Type 2 Diabetes: 2015 Interim Update Journal Articles
- Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials Journal Articles
- CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis Journal Articles
- Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-Analysis. Journal Articles
- Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From aDiabetes CareEditors’ Expert Forum Journal Articles
-
Cardiovascular events and all‐cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs:
A B ayesian meta‐analysis of survival data Journal Articles - Cardiovascular, Kidney, and Safety Outcomes With GLP-1 Receptor Agonists Alone and in Combination With SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis. Journal Articles
- Comparative effectiveness of SGLT2i versus GLP1-RA on cardiovascular outcomes in routine clinical practice Journal Articles
- Effect of Canagliflozin on Heart Failure Hospitalization in Diabetes According to Baseline Heart Failure Risk Journal Articles
- Effects of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on cardiovascular and kidney outcomes in Asian versus White patients with type 2 diabetes mellitus Journal Articles
- Efficacy and safety of dapagliflozin were similar in patients with type 2 DM and atherosclerotic CVD, regardless of PAD Journal Articles
- Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial Journal Articles
- Eligibility and Projected Benefits of Rapid Initiation of Quadruple Therapy for Newly Diagnosed Heart Failure Journal Articles
- Exploring the Experiences of Adults With Type 2 Diabetes on Sodium Glucose Cotransporter 2 Inhibitors Journal Articles
- Fracture Risk of Sodium-Glucose Cotransporter-2 Inhibitors in Chronic Kidney Disease Journal Articles
- In-hospital initiation of sodium-glucose co-transporter-2 inhibitors in patients with acute heart failure. Journal Articles
- Management of mitochondrial diabetes in the era of novel therapies Journal Articles
- Patient data from routinely collected medical records complement evidence from SGLT2 inhibitor outcome trials Journal Articles
- Policies, Guidelines and Consensus Statements: Pharmacologic Management of Type 2 Diabetes–2015 Interim Update Journal Articles
- Predictive models for cardiovascular and kidney outcomes in patients with type 2 diabetes: systematic review and meta-analyses Journal Articles
- Rationale and design of NUDGE-CKD: A nationwide randomized factorial trial of electronic nudges for increasing guideline-directed medical therapy in chronic kidney disease. Journal Articles
- Reduction in heart failure outcomes with SGLT2 inhibitors irrespective of glycaemic status Journal Articles
- SGLT2 Inhibitors and Risk for Hyperkalemia Among Individuals Receiving RAAS Inhibitors. Journal Articles
- SGLT2 inhibitors improved health status in Black and White patients with HF regardless of race Journal Articles
- Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials Journal Articles
- Sodium-glucose cotransporter-2 (SGLT-2) inhibitors for adults with chronic kidney disease: a clinical practice guideline. Journal Articles
- Sodium‐Glucose Co‐Transporter Inhibitors and Atrial Fibrillation: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials Journal Articles
- Sodium–Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure Journal Articles
- Sodium–glucose cotransporter-2 inhibitors in patients without diabetes Journal Articles
- Surgical and Advanced Medical Therapy for the Treatment of Type 2 Diabetes in Class I Obese Patients: a Short-Term Outcome Journal Articles
- The Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists on Cardiorenal Outcomes: Systematic Review and Meta-analysis Journal Articles
- The Na+/Glucose Cotransporter Inhibitor Canagliflozin Activates AMPK by Inhibiting Mitochondrial Function and Increasing Cellular AMP Levels Journal Articles
- The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy Journal Articles
- The SGLT2 inhibitor canagliflozin suppresses lipid synthesis and interleukin-1 beta in ApoE deficient mice Journal Articles
- The effectiveness of sodium-glucose co-transporter 2 inhibitors on cardiorenal outcomes: an updated systematic review and meta-analysis Journal Articles
- Use of sodium–glucose cotransporter-2 inhibitors and risk of acute kidney injury in older adults with diabetes: a population-based cohort study Journal Articles
- Values, preferences and burden of treatment for the initiation of GLP-1 receptor agonists and SGLT-2 inhibitors in adult patients with type 2 diabetes: a systematic review Journal Articles